drugset / Trial / NCT03505151
This Study in Healthy Men and Women Tests How the Body Takes up BI 409306
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this trial is to investigate the absolute bioavailability of BI 409306. The secondary objective is the evaluation and comparison of several pharmacokinetic parameters for the different treatments.
Timeline
- Start
- 2018-04-27
- Primary completion
- 2018-05-19
- Completion
- 2018-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OSORESNONTRINE | Small molecule | 0.1 mg | Intravenous |
| Subject | OSORESNONTRINE | Small molecule | 50 mg | Intravenous |
Indications
No indication recorded.